Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
J Clin Invest ; 134(1)2024 Jan 02.
Article in English | MEDLINE | ID: mdl-37856214

ABSTRACT

Cardiovascular diseases are the most common cause of worldwide morbidity and mortality, highlighting the necessity for advanced therapeutic strategies. Ca2+/calmodulin-dependent protein kinase IIδ (CaMKIIδ) is a prominent inducer of various cardiac disorders, which is mediated by 2 oxidation-sensitive methionine residues within the regulatory domain. We have previously shown that ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing enables the heart to recover function from otherwise severe damage following ischemia/reperfusion (IR) injury. Here, we extended this therapeutic concept toward potential clinical translation. We generated a humanized CAMK2D knockin mouse model in which the genomic sequence encoding the entire regulatory domain was replaced with the human sequence. This enabled comparison and optimization of two different editing strategies for the human genome in mice. To edit CAMK2D in vivo, we packaged the optimized editing components into an engineered myotropic adeno-associated virus (MyoAAV 2A), which enabled efficient delivery at a very low AAV dose into the humanized mice at the time of IR injury. CAMK2D-edited mice recovered cardiac function, showed improved exercise performance, and were protected from myocardial fibrosis, which was otherwise observed in injured control mice after IR. Our findings identify a potentially effective strategy for cardioprotection in response to oxidative damage.


Subject(s)
Cardiomyopathies , Cardiovascular Diseases , Mice , Animals , Humans , CRISPR-Cas Systems , Gene Editing , Heart , Cardiomyopathies/genetics , Cardiovascular Diseases/genetics
2.
Infect Immun ; 91(2): e0039222, 2023 02 16.
Article in English | MEDLINE | ID: mdl-36722979

ABSTRACT

Chlamydia trachomatis is the most common cause of infectious blindness and sexually transmitted bacterial infection globally. C. trachomatis contains a conserved chlamydial plasmid with eight coding sequences. Plasmid-cured Chlamydia strains are attenuated and display reduced infectivity in cell culture and in vivo genital infection of female mice. Mutants that do not express the plasmid-encoded proteins Pgp3, a secreted protein with unknown function, or Pgp4, a putative regulator of pgp3 and other chromosomal loci, display an infectivity defect similar to plasmid-deficient strains. Our objective was to determine the combined and individual contributions of Pgp3 and Pgp4 to this phenotype. Deletion of pgp3 and pgp4 resulted in an infectivity defect detected by competition assay in cell culture and in mice. The pgp3 locus was placed under the control of an anhydrotetracycline-inducible promoter to examine the individual contributions of Pgp3 and Pgp4 to infectivity. Expression of pgp3 was induced 100- to 1,000-fold after anhydrotetracycline administration, regardless of the presence or absence of pgp4. However, secreted Pgp3 was not detected when pgp4 was deleted, confirming a role for Pgp4 in Pgp3 secretion. We discovered that expression of pgp3 or pgp4 alone was insufficient to restore normal infectivity, which required expression of both Pgp3 and Pgp4. These results suggest Pgp3 and Pgp4 are both required for infectivity during C. trachomatis infection. Future studies are required to determine the mechanism by which Pgp3 and Pgp4 influence chlamydial infectivity as well as the potential roles of Pgp4-regulated loci.


Subject(s)
Chlamydia Infections , Chlamydia trachomatis , Animals , Female , Mice , Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Chlamydia Infections/microbiology , Chlamydia trachomatis/genetics , Chlamydia trachomatis/pathogenicity , Plasmids/genetics , Virulence/genetics
3.
Oncotarget ; 13: 707-722, 2022.
Article in English | MEDLINE | ID: mdl-35634245

ABSTRACT

Evolving understanding of head and neck squamous cell carcinoma (HNSCC) is leading to more specific diagnostic disease classifications. Among HNSCC caused by the human papilloma virus (HPV), tumors harboring defects in TRAF3 or CYLD are associated with improved clinical outcomes and maintenance of episomal HPV. TRAF3 and CYLD are negative regulators of NF-κB and inactivating mutations of either leads to NF-κB overactivity. Here, we developed and validated a gene expression classifier separating HPV+ HNSCCs based on NF-κB activity. As expected, the novel classifier is strongly enriched in NF-κB targets leading us to name it the NF-κB Activity Classifier (NAC). High NF-κB activity correlated with improved survival in two independent cohorts. Using NAC, tumors with high NF-κB activity but lacking defects in TRAF3 or CYLD were identified; thus, while TRAF3 or CYLD gene defects identify the majority of tumors with NF-κB activation, unknown mechanisms leading to NF-kB activity also exist. The NAC correctly classified the functional consequences of two novel CYLD missense mutations. Using a reporter assay, we tested these CYLD mutations revealing that their activity to inhibit NF-kB was equivalent to the wild-type protein. Future applications of the NF-κB Activity Classifier may be to identify HPV+ HNSCC patients with better or worse survival with implications for treatment strategies.


Subject(s)
Alphapapillomavirus , Head and Neck Neoplasms , Papillomavirus Infections , Deubiquitinating Enzyme CYLD/genetics , Deubiquitinating Enzyme CYLD/metabolism , Head and Neck Neoplasms/genetics , Humans , NF-kappa B/metabolism , Papillomaviridae/genetics , Papillomaviridae/metabolism , Papillomavirus Infections/complications , Papillomavirus Infections/genetics , Papillomavirus Infections/metabolism , Squamous Cell Carcinoma of Head and Neck/genetics , TNF Receptor-Associated Factor 3/genetics , TNF Receptor-Associated Factor 3/metabolism
4.
Am J Physiol Endocrinol Metab ; 311(2): E519-29, 2016 08 01.
Article in English | MEDLINE | ID: mdl-27406741

ABSTRACT

Growth hormone (GH) plays an essential role in controlling somatic growth and in regulating multiple physiological processes in humans and other species. Insulin-like growth factor I (IGF-I), a conserved, secreted 70-amino acid peptide, is a critical mediator of many of the biological effects of GH. Previous studies have demonstrated that GH rapidly and potently promotes IGF-I gene expression in rodents and in some other mammals through the transcription factor STAT5b, leading to accumulation of IGF-I mRNAs and production of IGF-I. Despite this progress, very little is known about how GH or other trophic factors control human IGF1 gene expression, in large part because of the absence of any cellular model systems that robustly express IGF-I. Here, we have addressed mechanisms of regulation of human IGF-I by GH after generating cells in which the IGF1 chromosomal locus has been incorporated into a mouse cell line. Using this model, we found that physiological levels of GH rapidly stimulate human IGF1 gene transcription and identify several potential transcriptional enhancers in chromatin that bind STAT5b in a GH-regulated way. Each of the putative enhancers also activates a human IGF1 gene promoter in reconstitution experiments in the presence of the GH receptor, STAT5b, and GH. Thus we have developed a novel experimental platform that now may be used to determine how human IGF1 gene expression is controlled under different physiological and pathological conditions.


Subject(s)
Growth Hormone/metabolism , Insulin-Like Growth Factor I/genetics , RNA, Messenger/metabolism , Receptors, Somatotropin/metabolism , STAT5 Transcription Factor/metabolism , Animals , Cell Line , Gene Expression Regulation , Growth Hormone/pharmacology , Humans , Insulin-Like Growth Factor I/drug effects , Mice , Mice, Transgenic , Promoter Regions, Genetic , RNA, Messenger/drug effects , Receptors, Somatotropin/drug effects , Reverse Transcriptase Polymerase Chain Reaction , STAT5 Transcription Factor/drug effects , Transcription, Genetic
5.
Physiol Genomics ; 48(2): 167-72, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26645089

ABSTRACT

Insulin-like growth factor-2 (IGF2) is highly expressed in skeletal muscle and was identified as a quantitative trait locus for muscle mass. Yet little is known about mechanisms of its regulation in muscle. Recently, a DNA segment found ∼100 kb from the Igf2 gene was identified as a possible muscle transcriptional control element. Here we have developed an in vivo reporter system to assess this putative enhancer by substituting nuclear (n) EGFP for Igf2 coding exons in a bacterial artificial chromosome containing the mouse Igf2 - H19 chromosomal locus. After stable transfection into a mesenchymal stem cell line, individual clones were converted to myoblasts and underwent progressive muscle-specific gene expression and myotube formation in differentiation medium. Transgenic mRNA and nuclear-targeted enhanced green fluorescent protein were produced coincident with endogenous Igf2 mRNA, but only in lines containing an intact distal conserved DNA element. Our results show that a 294 bp DNA fragment containing two E-boxes is a necessary and sufficient long-range enhancer for induction of Igf2 gene transcription during skeletal muscle differentiation and provides a robust experimental platform for its further functional dissection.


Subject(s)
Enhancer Elements, Genetic , Insulin-Like Growth Factor II/genetics , Muscles/metabolism , Animals , Cell Differentiation , Cell Nucleus/metabolism , Chromosomes/metabolism , Culture Media , Exons , Gene Expression Regulation , Green Fluorescent Proteins/metabolism , Immunohistochemistry , Mice , Mice, Transgenic , Muscle Fibers, Skeletal/metabolism , Muscle, Skeletal/metabolism , RNA, Long Noncoding , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Transcription, Genetic
6.
Physiol Genomics ; 47(11): 559-68, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26330488

ABSTRACT

Growth hormone (GH) plays a central role in regulating somatic growth and in controlling multiple physiological processes in humans and other vertebrates. A key agent in many GH actions is the secreted peptide, IGF-I. As established previously, GH stimulates IGF-I gene expression via the Stat5b transcription factor, leading to production of IGF-I mRNAs and proteins. However, the precise mechanisms by which GH-activated Stat5b promotes IGF-I gene transcription have not been defined. Unlike other GH-regulated genes, there are no Stat5b sites near either of the two IGF-I gene promoters. Although dispersed GH-activated Stat5b binding elements have been mapped in rodent Igf1 gene chromatin, it is unknown how these distal sites might function as potential transcriptional enhancers. Here we have addressed mechanisms of regulation of IGF-I gene transcription by GH by generating cell lines in which the rat Igf1 chromosomal locus has been incorporated into the mouse genome. Using these cells we find that physiological levels of GH rapidly and potently activate Igf1 gene transcription while stimulating physical interactions in chromatin between inducible Stat5b-binding elements and the Igf1 promoters. We have thus developed a robust experimental platform for elucidating how dispersed transcriptional enhancers control Igf1 gene expression under different biological conditions.


Subject(s)
Enhancer Elements, Genetic , Growth Hormone/physiology , Insulin-Like Growth Factor I/genetics , Animals , Male , Promoter Regions, Genetic , Rats , Rats, Sprague-Dawley , Transcription, Genetic/physiology , Transgenes
7.
PLoS One ; 7(11): e50278, 2012.
Article in English | MEDLINE | ID: mdl-23185594

ABSTRACT

Many of the biological effects of growth hormone (GH) are mediated by insulin-like growth factor I (IGF-I), a 70-amino acid secreted peptide whose gene expression is rapidly induced by GH via the Stat5b transcription factor. We previously identified multiple evolutionarily conserved GH-activated chromosomal binding domains for Stat5b within the rat Igf1 locus, and proposed that they could regulate IGF-I gene activity. Here we investigate the biochemical and functional characteristics of these putative long-range transcriptional enhancers. Each element contained 2 or 3 individual Stat5b recognition sequences that could bind Stat5b in vitro, but with affinities that varied over a >100-fold range. Full transcriptional responsiveness to GH required that all Stat5b sites be intact within an individual enhancer. Replacement of a single lower-affinity Stat5b sequence with a higher-affinity one increased in vitro binding of Stat5b, and boosted transcriptional potency of the entire element to GH. As enhanced transcriptional activity involved changes in only one or two nucleotides within an enhancer DNA segment, there appears to be remarkable specificity and sensitivity in the ability of Stat5b to transform DNA binding activity into transcriptional function. Stat5b was able to stimulate the transcriptional activity of two enhancers in the absence of GH, indicating that individual Stat5b-regulated elements possess distinct functional features. We conclude that combinatorial interplay among multiple Stat5b-binding response elements with distinguishable biochemical properties is responsible for highly regulated control of IGF-I gene activity by GH.


Subject(s)
Enhancer Elements, Genetic , Growth Hormone/genetics , Insulin-Like Growth Factor I/genetics , STAT5 Transcription Factor/genetics , Transcription, Genetic , Animals , Binding Sites , COS Cells , Chlorocebus aethiops , Gene Expression Regulation , Genes, Reporter , Genetic Loci , Growth Hormone/metabolism , Insulin-Like Growth Factor I/metabolism , Kinetics , Luciferases , Mice , Protein Binding , Rats , STAT5 Transcription Factor/metabolism , Signal Transduction , Transfection
8.
Mol Endocrinol ; 25(1): 128-37, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21106882

ABSTRACT

Skeletal muscle differentiation and regeneration are regulated by interactions between exogenous hormone- and growth factor-activated signaling cascades and endogenous muscle-specific transcriptional programs. IGF-I and IGF-II can promote muscle differentiation in vitro and can enhance muscle maintenance and repair in vivo. In contrast, members of the TGF-ß superfamily prominently inhibit muscle differentiation and regeneration. In this study, we have evaluated functional interactions between IGF- and TGF-ß-regulated signaling pathways during skeletal muscle differentiation. In the mouse C2 muscle cell line and in human myoblasts in primary culture, addition of TGF-ß1 blocked differentiation in a dose-dependent way, inhibited expression of muscle-specific mRNAs and proteins, and impaired myotube formation. TGF-ß1 also diminished stimulation of IGF-II gene expression in myoblasts, decreased IGF-II secretion, and reduced IGF-I receptor activation. To test the hypothesis that TGF-ß1 prevents muscle differentiation primarily by blocking IGF-II production, we examined effects of IGF analogues on TGF-ß actions in myoblasts. Although both IGF-I and IGF-II restored muscle gene and protein expression, and stimulated myotube formation in the presence of TGF-ß1, they did not reduce TGF-ß1-stimulated signaling, as measured by no decline in phosphorylation of SMA and mothers against decapentaplegic homolog (Smad)3, or in induction of TGF-ß-activated target genes, including a Smad-dependent promoter-reporter plasmid. Our results demonstrate that TGF-ß disrupts an IGF-II-stimulated autocrine amplification cascade that is necessary for muscle differentiation in vitro. Because this inhibitory pathway can be overcome by exogenous IGFs, our observations point toward potential strategies to counteract disorders that reduce muscle mass and strength.


Subject(s)
Autocrine Communication/drug effects , Cell Differentiation/drug effects , Insulin-Like Growth Factor II/metabolism , Muscle, Skeletal/cytology , Muscle, Skeletal/metabolism , Transforming Growth Factor beta/pharmacology , Animals , Humans , Insulin-Like Growth Factor Binding Proteins/metabolism , Insulin-Like Growth Factor I/pharmacology , Insulin-Like Growth Factor II/biosynthesis , Mice , Models, Biological , Muscle, Skeletal/drug effects , Myoblasts/cytology , Myoblasts/drug effects , Myoblasts/metabolism , Sus scrofa , Up-Regulation/drug effects
9.
J Biol Chem ; 285(50): 38969-77, 2010 Dec 10.
Article in English | MEDLINE | ID: mdl-20937833

ABSTRACT

The differentiation, maintenance, and repair of skeletal muscle is controlled by interactions between genetically determined transcriptional programs regulated by myogenic transcription factors and environmental cues activated by growth factors and hormones. Signaling through the insulin-like growth factor 1 (IGF1) receptor by locally produced IGF2 defines one such pathway that is critical for normal muscle growth and for regeneration after injury. IGF2 gene and protein expression are induced as early events in muscle differentiation, but the responsible molecular mechanisms are unknown. Here we characterize a distal DNA element within the imprinted mouse Igf2-H19 locus with properties of a muscle transcriptional enhancer. We find that this region undergoes a transition to open chromatin during differentiation, whereas adjacent chromatin remains closed, and that it interacts in differentiating muscle nuclei but not in mesenchymal precursor cells with the Igf2 gene found more than 100 kb away, suggesting that chromatin looping or sliding to bring the enhancer in proximity to Igf2 promoters is also an early event in muscle differentiation. Because this element directly stimulates the transcriptional activity of an Igf2 promoter-reporter gene in differentiating myoblasts, our results indicate that we have identified a bona fide distal transcriptional enhancer that supports Igf2 gene activation in skeletal muscle cells. Because this DNA element is conserved in the human IGF2-H19 locus, our results further suggest that its muscle enhancer function also is conserved among different mammalian species.


Subject(s)
Cell Differentiation , Gene Expression Regulation , Insulin-Like Growth Factor II/metabolism , Muscle, Skeletal/metabolism , Transcription, Genetic , Animals , Cells, Cultured , Chromatin/chemistry , Chromatin/metabolism , Female , Humans , Male , Mice , Mice, Inbred C57BL , Models, Genetic , Promoter Regions, Genetic , Reverse Transcriptase Polymerase Chain Reaction
10.
BMC Microbiol ; 9: 2, 2009 Jan 05.
Article in English | MEDLINE | ID: mdl-19123944

ABSTRACT

BACKGROUND: The chlamydiae alter many aspects of host cell biology, including the division process, but the molecular biology of these alterations remains poorly characterized. Chlamydial inclusion membrane proteins (Incs) are likely candidates for direct interactions with host cell cytosolic proteins, as they are secreted to the inclusion membrane and exposed to the cytosol. The inc gene CT223 is one of a sequential set of orfs that encode or are predicted to encode Inc proteins. CT223p is localized to the inclusion membrane in all tested C. trachomatis serovars. RESULTS: A plasmid transfection approach was used to examine the function of the product of CT223 and other Inc proteins within uninfected mammalian cells. Fluorescence microscopy was used to demonstrate that CT223, and, to a lesser extent, adjacent inc genes, are capable of blocking host cell cytokinesis and facilitating centromere supranumeracy defects seen by others in chlamydiae-infected cells. Both phenotypes were associated with transfection of plasmids encoding the carboxy-terminal tail of CT223p, a region of the protein that is likely exposed to the cytosol in infected cells. CONCLUSION: These studies suggest that certain Inc proteins block cytokinesis in C. trachomatis-infected cells. These results are consistent with the work of others showing chlamydial inhibition of host cell cytokinesis.


Subject(s)
Bacterial Proteins/metabolism , Chlamydia Infections/microbiology , Chlamydia Infections/physiopathology , Chlamydia trachomatis , Cytokinesis/physiology , Cell Line , Centrosome , Chlamydia trachomatis/genetics , Chlamydia trachomatis/metabolism , Cytosol/metabolism , Gene Expression Regulation , Genes, Bacterial/genetics , HeLa Cells , Humans , Phenotype , Protein Transport , Transfection
11.
J Microbiol Methods ; 68(1): 201-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16997404

ABSTRACT

This manuscript describes a new technique for the microbiological cloning of chlamydia-infected cells using a fluorescence activated cell sorter (FACS). The approach exploits chlamydial acquisition of the fluorescent, Golgi-specific, stain 6-((N-7-(-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-hexanoyl)sphingosine (C6-NBD-cer). This fluorescent lipid is delivered from the Golgi apparatus to the chlamydial inclusion membrane and then to the developmental forms within the inclusion in living, infected cells. Labeling with C6-NBD-cer results in easily identifiable chlamydial inclusions that can then be analyzed and sorted by FACS. This technique was used successfully to sort individual chlamydia-infected cells into individual wells of a culture dish and, in this experimental system, resulted in the isolation of cloned chlamydial isolates. FACS-based sorting was used to isolate clonal populations of prototype strains from Chlamydia trachomatis, C. caviae and C. suis. Recent clinical isolates were also successfully cloned using FACS. The procedure is simple and rapid, with single cloning cycles being completed 24 h post-culture of a sample. It is anticipated that FACS-based sorting of live chlamydia-infected cells will be a significant technical tool for the isolation of clonal populations of any chlamydial strain.


Subject(s)
4-Chloro-7-nitrobenzofurazan/analogs & derivatives , Ceramides/metabolism , Chlamydia Infections/microbiology , Chlamydia trachomatis/growth & development , Flow Cytometry/methods , Fluorescent Dyes/metabolism , 4-Chloro-7-nitrobenzofurazan/metabolism , Cell Line , Chlamydia Infections/metabolism , Chlamydia Infections/pathology , Chlamydia trachomatis/metabolism , Clone Cells , Humans , Staining and Labeling/methods
12.
Infect Immun ; 73(7): 3954-62, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15972482

ABSTRACT

The chlamydiae are obligate intracellular bacteria that occupy a non-acidified vacuole (the inclusion) during their entire developmental cycle. These bacteria produce a set of proteins (Inc proteins) that localize to the surface of the inclusion within infected cells. Chlamydia trachomatis IncA is also commonly found in long fibers that extend away from the inclusion. We used standard and confocal immunofluorescence microscopy to demonstrate that these fibers extend to newly developed inclusions, termed secondary inclusions, within infected cells. Secondary inclusions observed at early time points postinfection were devoid of chlamydial reticulate bodies. Later in the developmental cycle, secondary inclusions containing variable numbers of reticulate bodies were common. Reticulate bodies were also observed within the IncA-laden fibers connecting primary and secondary inclusions. Quantitative differences in secondary inclusion formation were found among clinical isolates, and these differences were associated with serovar. Isolates of serovar G consistently produced secondary inclusions at the highest frequency (P < 0.0001). Similar quantitative studies demonstrated that secondary inclusion formation was associated with segregation of inclusions to daughter cells following cytokinesis. We conclude that the production of secondary inclusions via IncA-laden fibers allows chlamydiae to generate an expanded intracellular niche in which they can grow and may provide a means for continuous infection within progeny cells following cell division.


Subject(s)
Chlamydia trachomatis/growth & development , Inclusion Bodies/microbiology , Bacterial Proteins/physiology , Humans , Membrane Proteins/physiology , Vacuoles/microbiology
13.
BMC Microbiol ; 4: 24, 2004 Jul 01.
Article in English | MEDLINE | ID: mdl-15230981

ABSTRACT

BACKGROUND: Chlamydiae produce a set of proteins, termed Inc proteins, that are localized to the inclusion membrane and exposed to the host cell cytosol. Little information exists regarding the interaction of Inc proteins with the eukaryotic cell. To examine these interactions, Vaccinia virus vectors and mammalian plasmid-based systems were used to express inc genes in mammalian cells. RESULTS: Cells transfected with plasmids expressing Chlamydophila caviae incA were not productively infected by C. caviae. Expression of C. caviae incA also reduced inclusion formation by Chlamydia trachomatis, but not to the degree seen for C. caviae. Chlamydia trachomatis incA did not block development of either C. trachomatis or C. caviae. Deletion mutagenesis was used to demonstrate that plasmids encoding either the amino or carboxy-terminal regions of the protein, as well as the changing of a single amino acid within IncA (serine 17) could not block C. caviae infection. Immunoblot analysis of truncated IncA in a Vaccinia virus system provided evidence that serine 17 of C. caviae IncA is a target for phosphorylation. CONCLUSIONS: These experiments provide insight into the interaction of Inc proteins with the host cell and introduce a model system where these interactions can be explored further.


Subject(s)
Bacterial Proteins/genetics , Chlamydophila/genetics , HeLa Cells/microbiology , Phosphoproteins/genetics , Animals , Bacterial Proteins/biosynthesis , CHO Cells , Cell Line , Cell Line, Tumor , Chlamydia trachomatis/genetics , Chlamydia trachomatis/growth & development , Chlamydophila/growth & development , Cricetinae , Cricetulus , Cytoplasm/chemistry , Cytoplasm/metabolism , Cytoplasm/microbiology , Genetic Vectors/biosynthesis , HeLa Cells/chemistry , HeLa Cells/metabolism , HeLa Cells/virology , Humans , Membrane Proteins/biosynthesis , Membrane Proteins/genetics , Models, Genetic , Phosphoproteins/biosynthesis , Transfection/methods , Vaccinia virus/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...